Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Ethanol | HCID 702 | — |
| Reactant | 4-Methylmorpholine | HCID 7972 | — |
| Reactant | Sodium ethoxide | HCID 2723922 | — |
| Reactant | 1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochloride | HCID 2723939 | — |
| Reactant | 2H-1,2,4-Benzothiadiazine-3-acetic acid, 7-[(methylsulfonyl)amino]-, 1,1-dioxide | HCID 24858539 | — |
| Reactant | HCID 59555492 | HCID 59555492 | — |
| Solvent | Hydrochloric Acid | HCID 313 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 135857093 | HCID 135857093 | 39% |
Reaction Steps
A solution of 1-[(4-fluoro-benzylamino)-methyl]-cyclopropanecarboxylic acid ethyl ester (72 mg, 0.29 mmol) and (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (105 mg, 0.32 mmol) in anhydrous N,N-dimethylformamide (4 mL) was treated sequentially with N-methylmorpholine (70 μL, 0.64 mmol) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (61 mg, 0.32 mmol). The reaction mixture was stirred at 25° C. for 1 h, diluted with a 1.0 M aqueous hydrochloric acid solution (20 mL), and extracted with ethyl acetate (3×30 mL). The combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was dissolved in ethanol (5 mL), treated with a 21 wt % solution of sodium ethoxide in ethanol (0.5 mL, 1.37 mmol). The reaction was stirred and heated at 60° C. for 1.5 h, allowed to cool to 25° C., and quenched with a 0.5 M aqueous hydrochloric acid solution (10 mL). The resulting mixture was extracted with ethyl acetate (3×30 mL) and the combined organic layers were washed with brine (20 mL), dried over sodium sulfate, filtered, and concentrated in vacuo. The crude residue was purified by prep-HPLC {Column Luna 5μ C18 (2) 100 Å AXIA 150×21.2 mm, 5 micron, 30-100% in 7 min @ 30 mL/min flow rate, 0.05% trifluoroacetic acid in acetonitrile/0.05% trifluoroacetic acid in water] to give N-{3-[5-(4-fluoro-benzyl)-8-hydroxy-6-oxo-5-aza-spiro[2.5]oct-7-en-7-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (58 mg, 39%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ: 0.97 (br s, 2H), 1.34 (br s, 2H), 3.06 (s, 3H), 3.41 (s, 2H), 4.65 (s, 2H), 7.17 (t, J=8.8 Hz, 2H), 7.36 (dd, J1=8.8 Hz, J2=5.4 Hz, 2H), 7.51 (dd, J1=8.4 Hz, J2=2.4 Hz, 1H), 7.57-7.60 (m, 2H), 10.16 (s, 1H), 13.86 (br s, 1H). LC-MS (ESI) calculated for C22H21FN4O6S2: 520.1, found 521.3 [M+H+].
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07834009B2 |
|---|
| Source dataset | uspto-grants-2010_11 |
|---|
| ORD ID | ord-544862a3aefa465eb6d8410a2140f883 |
|---|
| Source note | uspto-grants-2010_11 |
|---|